[144] Axon Enterprise, Inc. SEC Filing
In this Form 144 notice for Axon Enterprise, Inc., the filer reports an intended sale of 10,000 shares of common stock through UBS Financial Services on Nasdaq with an aggregate market value of $8,428,900 and an approximate sale date of 08/11/2025. The shares were acquired on 11/15/2021 via an option exercise and paid in cash. The filing lists 78,504,440 shares outstanding, so the proposed sale represents about 0.0127% of outstanding shares.
The form shows no securities sold by the filer in the past three months and includes the standard Rule 144 representation that the filer does not possess undisclosed material adverse information. A broker is named and the transaction mechanics (option exercise, cash payment) are disclosed.
In questo avviso Form 144 per Axon Enterprise, Inc., il dichiarante segnala l'intenzione di vendere 10,000 azioni ordinarie tramite UBS Financial Services sul Nasdaq, con un valore di mercato complessivo di $8,428,900 e una data di vendita approssimativa del 08/11/2025. Le azioni sono state acquisite il 11/15/2021 mediante esercizio di opzione e pagate in contanti. La comunicazione indica 78,504,440 azioni in circolazione, quindi la vendita proposta rappresenta circa il 0.0127% delle azioni in circolazione.
Il modulo non riporta vendite di titoli da parte del dichiarante negli ultimi tre mesi e include la dichiarazione prevista dalla Regola 144 secondo cui il dichiarante non 猫 in possesso di informazioni rilevanti non divulgate. 脠 indicato un broker e sono specificate le modalit脿 della transazione (esercizio dell'opzione, pagamento in contanti).
En este aviso Form 144 para Axon Enterprise, Inc., el declarante informa la intenci贸n de vender 10,000 acciones ordinarias a trav茅s de UBS Financial Services en el Nasdaq, con un valor de mercado agregado de $8,428,900 y una fecha aproximada de venta del 08/11/2025. Las acciones fueron adquiridas el 11/15/2021 mediante ejercicio de opciones y pagadas en efectivo. La presentaci贸n indica 78,504,440 acciones en circulaci贸n, por lo que la venta propuesta representa cerca del 0.0127% del total en circulaci贸n.
El formulario no refleja ventas de valores por parte del declarante en los 煤ltimos tres meses e incluye la declaraci贸n est谩ndar de la Regla 144 de que el declarante no posee informaci贸n material adversa no divulgada. Se nombra un corredor y se detallan las modalidades de la operaci贸n (ejercicio de la opci贸n, pago en efectivo).
Axon Enterprise, Inc.鞐� 雽�頃� 氤� Form 144 韱奠鞐愳劀 鞝滌稖鞚胳潃 UBS Financial Services毳� 韱淀暣 雮橃姢雼レ棎靹� 10,000欤检潣 氤错喌欤茧ゼ 毵る弰頃� 鞓堨爼鞚措┌, 齑� 鞁滉皜臧� $8,428,900鞚搓碃 雽�霝奠爜鞚� 毵る弰 鞓堨爼鞚检潃 08/11/2025霛缄碃 氤搓碃頄堨姷雼堧嫟. 頃措嫻 欤检嫕鞚� 11/15/2021鞐� 鞓奠厴 頄夓偓搿� 旆摑霅橃棃瓿� 順勱笀鞙茧 歆�旮夒悩鞐堨姷雼堧嫟. 鞝滌稖靹滊鞐愲姅 78,504,440欤检潣 氚滍枆欤检嫕鞚� 旮办灛霅橃柎 鞛堨柎, 鞝滌晥霅� 毵る弰電� 氚滍枆欤检嫕鞚� 鞎� 0.0127%鞐� 頃措嫻頃╇媹雼�.
頃措嫻 鞏戩嫕鞐愲姅 鞝滌稖鞚胳澊 斓滉芳 3臧滌洈 雮挫棎 韺愲Г頃� 歃濌秾鞚� 鞐嗠嫟瓿� 旮办灛霅橃柎 鞛堨溂氅�, 鞝滌稖鞚胳澊 氙戈车臧� 欤检殧 攵堧Μ頃� 鞝曤炒毳� 氤挫湢頃橁碃 鞛堨 鞎婋嫟電� Rule 144鞚� 響滌 歆勳垹鞚� 韽暔頃╇媹雼�. 欷戧皽鞚胳澊 氇呾嫓霅橃柎 鞛堦碃 瓯半灅鞚� 氅旍护雼堨(鞓奠厴 頄夓偓, 順勱笀 歆�旮�)鞚� 瓿店皽霅橃柎 鞛堨姷雼堧嫟.
Dans cet avis Form 144 concernant Axon Enterprise, Inc., le d茅clarant indique son intention de vendre 10,000 actions ordinaires via UBS Financial Services sur le Nasdaq, pour une valeur marchande totale de $8,428,900 et une date de vente approximative fix茅e au 08/11/2025. Les actions ont 茅t茅 acquises le 11/15/2021 par exercice d'option et pay茅es en esp猫ces. Le d茅p么t mentionne 78,504,440 actions en circulation ; la vente propos茅e repr茅sente donc environ 0.0127% des actions en circulation.
Le formulaire n'indique aucune vente de titres par le d茅clarant au cours des trois derniers mois et inclut la d茅claration standard de la Rule 144 selon laquelle le d茅clarant ne d茅tient pas d'information d茅favorable importante non divulgu茅e. Un courtier est nomm茅 et les modalit茅s de la transaction (exercice de l'option, paiement en esp猫ces) sont pr茅cis茅es.
In dieser Form-144-Mitteilung f眉r Axon Enterprise, Inc. berichtet der Einreichende 眉ber die beabsichtigte Ver盲u脽erung von 10,000 Stammaktien 眉ber UBS Financial Services an der Nasdaq mit einem zusammengefassten Marktwert von $8,428,900 und einem voraussichtlichen Verkaufstermin am 08/11/2025. Die Aktien wurden am 11/15/2021 durch Aus眉bung einer Option erworben und bar bezahlt. Die Einreichung weist 78,504,440 ausstehende Aktien aus, sodass der vorgeschlagene Verkauf etwa 0.0127% der ausstehenden Aktien entspricht.
Das Formular verzeichnet keine vom Einreichenden in den letzten drei Monaten verkauften Wertpapiere und enth盲lt die standardm盲脽ige Erkl盲rung nach Rule 144, dass der Einreichende keine nicht offengelegten wesentlichen nachteiligen Informationen besitzt. Ein Broker ist genannt und die Transaktionsmodalit盲ten (Optionsaus眉bung, Barzahlung) sind offengelegt.
- Regulatory compliance: Sale is filed under Rule 144 and identifies a broker (UBS), indicating formal disclosure and adherence to resale rules.
- Small relative size: 10,000 shares represent approximately 0.0127% of the 78,504,440 shares outstanding, limiting potential market impact.
- Insider sale disclosed: The filer is selling shares (aggregate value reported as $8,428,900); some investors may view insider sales negatively despite the small percentage of outstanding shares.
Insights
TL;DR Insider sale disclosed under Rule 144; the size is trivial relative to outstanding shares and unlikely to move the market.
The filer intends to sell 10,000 common shares valued at $8,428,900 via UBS with an approximate sale date of 08/11/2025. These shares were acquired by option exercise on 11/15/2021 and paid in cash, which clarifies consideration. Relative to 78,504,440 shares outstanding, the sale equals ~0.0127%, a negligible supply change. No sales were reported in the past three months, reducing evidence of sustained insider divestiture. Overall, informational and procedural clarity is present; impact on valuation or liquidity appears minimal.
TL;DR The filing demonstrates compliance with Rule 144; disclosure is standard and does not show governance concerns from this notice alone.
The Form 144 names the broker (UBS Financial Services) and discloses acquisition via option exercise and cash payment, which are straightforward facts supporting transparency. The filer affirms no undisclosed material adverse information, and no reliance date for a 10b5-1 plan is provided on the form. From a governance perspective, the document is a routine insider liquidity disclosure and does not, by itself, indicate irregular insider activity or material corporate governance issues.
In questo avviso Form 144 per Axon Enterprise, Inc., il dichiarante segnala l'intenzione di vendere 10,000 azioni ordinarie tramite UBS Financial Services sul Nasdaq, con un valore di mercato complessivo di $8,428,900 e una data di vendita approssimativa del 08/11/2025. Le azioni sono state acquisite il 11/15/2021 mediante esercizio di opzione e pagate in contanti. La comunicazione indica 78,504,440 azioni in circolazione, quindi la vendita proposta rappresenta circa il 0.0127% delle azioni in circolazione.
Il modulo non riporta vendite di titoli da parte del dichiarante negli ultimi tre mesi e include la dichiarazione prevista dalla Regola 144 secondo cui il dichiarante non 猫 in possesso di informazioni rilevanti non divulgate. 脠 indicato un broker e sono specificate le modalit脿 della transazione (esercizio dell'opzione, pagamento in contanti).
En este aviso Form 144 para Axon Enterprise, Inc., el declarante informa la intenci贸n de vender 10,000 acciones ordinarias a trav茅s de UBS Financial Services en el Nasdaq, con un valor de mercado agregado de $8,428,900 y una fecha aproximada de venta del 08/11/2025. Las acciones fueron adquiridas el 11/15/2021 mediante ejercicio de opciones y pagadas en efectivo. La presentaci贸n indica 78,504,440 acciones en circulaci贸n, por lo que la venta propuesta representa cerca del 0.0127% del total en circulaci贸n.
El formulario no refleja ventas de valores por parte del declarante en los 煤ltimos tres meses e incluye la declaraci贸n est谩ndar de la Regla 144 de que el declarante no posee informaci贸n material adversa no divulgada. Se nombra un corredor y se detallan las modalidades de la operaci贸n (ejercicio de la opci贸n, pago en efectivo).
Axon Enterprise, Inc.鞐� 雽�頃� 氤� Form 144 韱奠鞐愳劀 鞝滌稖鞚胳潃 UBS Financial Services毳� 韱淀暣 雮橃姢雼レ棎靹� 10,000欤检潣 氤错喌欤茧ゼ 毵る弰頃� 鞓堨爼鞚措┌, 齑� 鞁滉皜臧� $8,428,900鞚搓碃 雽�霝奠爜鞚� 毵る弰 鞓堨爼鞚检潃 08/11/2025霛缄碃 氤搓碃頄堨姷雼堧嫟. 頃措嫻 欤检嫕鞚� 11/15/2021鞐� 鞓奠厴 頄夓偓搿� 旆摑霅橃棃瓿� 順勱笀鞙茧 歆�旮夒悩鞐堨姷雼堧嫟. 鞝滌稖靹滊鞐愲姅 78,504,440欤检潣 氚滍枆欤检嫕鞚� 旮办灛霅橃柎 鞛堨柎, 鞝滌晥霅� 毵る弰電� 氚滍枆欤检嫕鞚� 鞎� 0.0127%鞐� 頃措嫻頃╇媹雼�.
頃措嫻 鞏戩嫕鞐愲姅 鞝滌稖鞚胳澊 斓滉芳 3臧滌洈 雮挫棎 韺愲Г頃� 歃濌秾鞚� 鞐嗠嫟瓿� 旮办灛霅橃柎 鞛堨溂氅�, 鞝滌稖鞚胳澊 氙戈车臧� 欤检殧 攵堧Μ頃� 鞝曤炒毳� 氤挫湢頃橁碃 鞛堨 鞎婋嫟電� Rule 144鞚� 響滌 歆勳垹鞚� 韽暔頃╇媹雼�. 欷戧皽鞚胳澊 氇呾嫓霅橃柎 鞛堦碃 瓯半灅鞚� 氅旍护雼堨(鞓奠厴 頄夓偓, 順勱笀 歆�旮�)鞚� 瓿店皽霅橃柎 鞛堨姷雼堧嫟.
Dans cet avis Form 144 concernant Axon Enterprise, Inc., le d茅clarant indique son intention de vendre 10,000 actions ordinaires via UBS Financial Services sur le Nasdaq, pour une valeur marchande totale de $8,428,900 et une date de vente approximative fix茅e au 08/11/2025. Les actions ont 茅t茅 acquises le 11/15/2021 par exercice d'option et pay茅es en esp猫ces. Le d茅p么t mentionne 78,504,440 actions en circulation ; la vente propos茅e repr茅sente donc environ 0.0127% des actions en circulation.
Le formulaire n'indique aucune vente de titres par le d茅clarant au cours des trois derniers mois et inclut la d茅claration standard de la Rule 144 selon laquelle le d茅clarant ne d茅tient pas d'information d茅favorable importante non divulgu茅e. Un courtier est nomm茅 et les modalit茅s de la transaction (exercice de l'option, paiement en esp猫ces) sont pr茅cis茅es.
In dieser Form-144-Mitteilung f眉r Axon Enterprise, Inc. berichtet der Einreichende 眉ber die beabsichtigte Ver盲u脽erung von 10,000 Stammaktien 眉ber UBS Financial Services an der Nasdaq mit einem zusammengefassten Marktwert von $8,428,900 und einem voraussichtlichen Verkaufstermin am 08/11/2025. Die Aktien wurden am 11/15/2021 durch Aus眉bung einer Option erworben und bar bezahlt. Die Einreichung weist 78,504,440 ausstehende Aktien aus, sodass der vorgeschlagene Verkauf etwa 0.0127% der ausstehenden Aktien entspricht.
Das Formular verzeichnet keine vom Einreichenden in den letzten drei Monaten verkauften Wertpapiere und enth盲lt die standardm盲脽ige Erkl盲rung nach Rule 144, dass der Einreichende keine nicht offengelegten wesentlichen nachteiligen Informationen besitzt. Ein Broker ist genannt und die Transaktionsmodalit盲ten (Optionsaus眉bung, Barzahlung) sind offengelegt.
FAQ
What did Axon (AXON) disclose in this Form 144?
How were the securities being sold originally acquired?
What proportion of Axon's outstanding shares does the sale represent?
Were any other securities sold by the filer in the past three months?
Which broker is handling the proposed sale?
